Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Accumulated Expenses: 2020-2024

Historic Accumulated Expenses for Relay Therapeutics (RLAY) over the last 5 years, with Dec 2024 value amounting to $21.2 million.

  • Relay Therapeutics' Accumulated Expenses fell 24.34% to $25.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $25.1 million, marking a year-over-year decrease of 24.34%. This contributed to the annual value of $21.2 million for FY2024, which is 42.62% up from last year.
  • Latest data reveals that Relay Therapeutics reported Accumulated Expenses of $21.2 million as of FY2024, which was up 42.62% from $14.9 million recorded in FY2023.
  • Relay Therapeutics' 5-year Accumulated Expenses high stood at $22.7 million for FY2022, and its period low was $5.8 million during FY2020.
  • Its 3-year average for Accumulated Expenses is $19.6 million, with a median of $21.2 million in 2024.
  • Per our database at Business Quant, Relay Therapeutics' Accumulated Expenses soared by 135.36% in 2021 and then tumbled by 34.41% in 2023.
  • Yearly analysis of 5 years shows Relay Therapeutics' Accumulated Expenses stood at $5.8 million in 2020, then skyrocketed by 135.36% to $13.6 million in 2021, then surged by 67.46% to $22.7 million in 2022, then slumped by 34.41% to $14.9 million in 2023, then skyrocketed by 42.62% to $21.2 million in 2024.